{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:13:13Z","timestamp":1770747193208,"version":"3.49.0"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVE<\/jats:title>\n                  <jats:p>Neonatal seizures are one of the most challenging problems for experts across the globe. Although there is no consensus on the \u201cideal\u201d treatment of neonatal seizures, phenobarbitone has been the drug of choice for decades. Unfortunately, although extensively studied in adults and children, levetiracetam lacks rigorous evaluation in the neonatal population, despite its frequent use as an off-label drug. The objective of this open-label, randomized, active-control, single-center, pragmatic trial was to compare the effectiveness of levetiracetam with phenobarbitone for term asphyxiated infants as a first-line drug.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>The participants included in this study were inborn term asphyxiated infants with seizures in the first 48 hours of life. Infants satisfying the inclusion criteria were randomized to receive levetiracetam (20 mg\/kg) or phenobarbitone (20 mg\/kg). Clinical seizure control was noted. Infants who failed to respond to the primary drug were given the other group drug.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 103 eligible infants, 82 were randomly assigned (44 levetiracetam group, 38 phenobarbitone group). Clinical seizure control with the primary drug and maintenance of the same for 24 hours was observed in 29 infants (65.9%) in the levetiracetam group and 13 infants (34.2%) in the phenobarbitone group (P &amp;lt; .05, relative risk 0.52, 95% confidence interval 0.32\u20130.84). Of the infants in the phenobarbitone group who did not respond to the primary drug, 57.8% were controlled after adding levetiracetam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Levetiracetam can be used with effectiveness as a first- and second-line drug in asphyxiated term infants. A more extensive study on pharmacokinetics and optimal regimen is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/hpeds.2021-006415","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T08:11:34Z","timestamp":1654675894000},"page":"647-653","source":"Crossref","is-referenced-by-count":9,"title":["Levetiracetam or Phenobarbitone as a First-Line Anticonvulsant in Asphyxiated Term Newborns? An Open-Label, Single-Center, Randomized, Controlled, Pragmatic Trial"],"prefix":"10.1542","volume":"12","author":[{"given":"Sukena","family":"Susnerwala","sequence":"first","affiliation":[{"name":"Department of Neonatology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmikant","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Londhe","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"2023112014481627100_b1","article-title":"Neonatal Seizures and Neonatal Syndromes","volume-title":"The Epilepsies: Seizures, Syndromes and Management","author":"Panayiotopoulos","year":"2005"},{"key":"2023112014481627100_b2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/jp.2016.183","article-title":"State of newborn health in India","volume":"36","author":"Sankar","year":"2016","journal-title":"J Perinatol"},{"issue":"2","key":"2023112014481627100_b3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pediatrneurol.2011.11.006","article-title":"Neonatal seizures: treatment practices among term and preterm infants","volume":"46","author":"Glass","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"4","key":"2023112014481627100_b4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.siny.2013.01.001","article-title":"Treatment of neonatal seizures","volume":"18","author":"van Rooij","year":"2013","journal-title":"Semin Fetal Neonatal Med"},{"issue":"5","key":"2023112014481627100_b5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1542\/peds.83.5.674","article-title":"Rapid sequential phenobarbital treatment of neonatal seizures","volume":"83","author":"Gilman","year":"1989","journal-title":"Pediatrics"},{"issue":"23","key":"2023112014481627100_b6","doi-asserted-by":"crossref","first-page":"15089","DOI":"10.1073\/pnas.222550499","article-title":"Antiepileptic drugs and apoptotic neurodegeneration in the developing brain","volume":"99","author":"Bittigau","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"2023112014481627100_b7","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2023112014481627100_b8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2023112014481627100_b9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"issue":"2","key":"2023112014481627100_b10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/medicina54020012","article-title":"Does levetiracetam administration prevent cardiac damage in adulthood rats following neonatal hypoxia\/ischemia-induced brain injury?","volume":"54","author":"Gurgul","year":"2018","journal-title":"Medicina (Kaunas)"},{"key":"2023112014481627100_b11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yebeh.2018.09.015","article-title":"A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic-ischemic encephalopathy","volume":"88","author":"Rao","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"1","key":"2023112014481627100_b12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2010.10.003","article-title":"Levetiracetam: safety and efficacy in neonatal seizures","volume":"15","author":"Ramantani","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"issue":"8","key":"2023112014481627100_b13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s13312-019-1586-3","article-title":"Levetiracetam versus Phenobarbitone in neonatal seizures - a randomised controlled trial","volume":"56","author":"Gowda","year":"2019","journal-title":"Indian Pediatr"},{"issue":"6","key":"2023112014481627100_b14","doi-asserted-by":"crossref","first-page":"e20193182","DOI":"10.1542\/peds.2019-3182","article-title":"Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial","volume":"145","author":"Sharpe","year":"2020","journal-title":"Pediatrics"},{"issue":"52","key":"2023112014481627100_b15","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1016\/j.vaccine.2019.05.031","article-title":"Neonatal seizures: case definition & guidelines for data collection, analysis, and presentation of immunization safety data","volume":"37","author":"Pellegrin","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"2023112014481627100_b16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12098-021-04039-2","article-title":"Neonatal seizures-perspective in low- and middle-income countries","volume":"89","author":"Vegda","year":"2022","journal-title":"Indian J Pediatr"},{"issue":"9","key":"2023112014481627100_b17","doi-asserted-by":"crossref","first-page":"e1273","DOI":"10.1016\/S2214-109X(21)00264-3","article-title":"Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh","volume":"9","author":"Thayyil","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2023112014481627100_b18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/B978-0-444-64029-1.00018-7","article-title":"Diagnosis of seizures and encephalopathy using conventional EEG and amplitude integrated EEG","volume":"162","author":"Boylan","year":"2019","journal-title":"Handb Clin Neurol"},{"issue":"12","key":"2023112014481627100_b19","doi-asserted-by":"crossref","first-page":"e2139604","DOI":"10.1001\/jamanetworkopen.2021.39604","article-title":"Effect of treatment of clinical seizures vs electrographic seizures in full-term and near-term neonates: a randomized clinical trial","volume":"4","author":"Hunt","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2023112014481627100_b20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0037-1608653","article-title":"A systematic review of the efficacy of levetiracetam in neonatal seizures","volume":"49","author":"McHugh","year":"2018","journal-title":"Neuropediatrics"},{"issue":"1","key":"2023112014481627100_b21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2008.07.008","article-title":"Antenatal and intrapartum risk factors for seizures in term newborns: a population-based study, California 1998-2002","volume":"154","author":"Glass","year":"2009","journal-title":"J Pediatr"},{"issue":"12","key":"2023112014481627100_b22","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dmcn.13215","article-title":"Seizure burden and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy","volume":"58","author":"Kharoshankaya","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"2023112014481627100_b23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pediatrneurol.2010.11.005","article-title":"Use of intravenous levetiracetam for management of acute seizures in neonates","volume":"44","author":"Khan","year":"2011","journal-title":"Pediatr Neurol"},{"issue":"6","key":"2023112014481627100_b24","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.18203\/2320-6012.ijrms20161763","article-title":"A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: pilot study","volume":"4","author":"Perveen","year":"2016","journal-title":"Int J Res Med Sci"},{"issue":"4","key":"2023112014481627100_b25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0883073810384263","article-title":"Levetiracetam for treatment of neonatal seizures","volume":"26","author":"Abend","year":"2011","journal-title":"J Child Neurol"},{"issue":"5","key":"2023112014481627100_b26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anpedi.2016.08.004","article-title":"Use of levetiracetam in neonatal seizures","volume":"86","author":"Lloreda-Garc\u00eda","year":"2017","journal-title":"Anales de Pediatria"},{"issue":"1","key":"2023112014481627100_b27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpeds.2011.03.057","article-title":"Pharmacokinetics of levetiracetam in neonates with seizures","volume":"159","author":"Merhar","year":"2011","journal-title":"J Pediatr"},{"issue":"6","key":"2023112014481627100_b28","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1528-1167.2006.00576.x","article-title":"Levetiracetam pharmacokinetics in neonates at birth","volume":"47","author":"Allegaert","year":"2006","journal-title":"Epilepsia"},{"issue":"2","key":"2023112014481627100_b29","first-page":"76","article-title":"Levetiracetam in neonatal seizures: a review","volume":"20","author":"Mruk","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"2023112014481627100_b30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNP.0000000000000525","article-title":"Assessing the feasibility of providing a real-time response to seizures detected with continuous long-term neonatal electroencephalography monitoring","volume":"36","author":"Sharpe","year":"2019","journal-title":"J Clin Neurophysiol"},{"issue":"1","key":"2023112014481627100_b31","doi-asserted-by":"crossref","first-page":"e022739","DOI":"10.1136\/bmjopen-2018-022739","article-title":"Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial","volume":"9","author":"Favrais","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"2023112014481627100_b32","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/j.1528-1167.2009.02132.x","article-title":"Interobserver agreement in neonatal seizure identification","volume":"50","author":"Malone","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"2023112014481627100_b33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/epi.16815","article-title":"The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures","volume":"62","author":"Pressler","year":"2021","journal-title":"Epilepsia"},{"issue":"3","key":"2023112014481627100_b34","doi-asserted-by":"crossref","first-page":"F187","DOI":"10.1136\/adc.2005.086314","article-title":"Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures","volume":"93","author":"Murray","year":"2008","journal-title":"Arch Dis Child Fetal Neonatal Ed"}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/12\/7\/647\/1573451\/hpeds.2021-006415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/12\/7\/647\/1573451\/hpeds.2021-006415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:49:33Z","timestamp":1700491773000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/12\/7\/647\/188253\/Levetiracetam-or-Phenobarbitone-as-a-First-Line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,6,8]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2021-006415","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"value":"2154-1663","type":"print"},{"value":"2154-1671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}